Postexposure Prophylaxis With Nirmatrelvir-Ritonavir Does Not Cut COVID-19 Infection
By Elana Gotkine HealthDay Reporter
THURSDAY, July 18, 2024 -- Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study published in the July 18 issue of the New England Journal of Medicine.
Jennifer Hammond, Ph.D., from Pfizer in Collegeville, Pennsylvania, and colleagues conducted a phase 2 to 3 double-blind trial to examine the efficacy and safety of nirmatrelvir-ritonavir in asymptomatic adults who had been exposed to a household contact with COVID-19 within 96 hours before randomization and were rapid antigen test-negative for COVID-19. Participants were randomly assigned to nirmatrelvir-ritonavir every 12 hours for five days (921 participants) or for 10 days (917 participants) or to matching placebo for five or 10 days (898 participants).
The researchers found that symptomatic, confirmed SARS-CoV-2 infection developed by day 14 in 2.6, 2.4, and 3.9 percent of participants in the five-day nirmatrelvir-ritonavir group, the 10-day nirmatrelvir-ritonavir group, and placebo group, respectively. The percentage of participants in whom symptomatic, confirmed SARS-CoV-2 infection developed did not differ significantly for each nirmatrelvir-ritonavir group versus the placebo group, with risk reductions relative to placebo of 29.8 and 35.5 percent in the five- and 10-day nirmatrelvir-ritonavir groups, respectively. The trial groups had a similar incidence of adverse events.
"Among adult household contacts of symptomatic persons with confirmed COVID-19, nirmatrelvir-ritonavir given as postexposure prophylaxis for five or 10 days did not significantly reduce the risk of development of SARS-CoV-2 infection as compared with placebo," the authors write.
The study was funded by Pfizer, the manufacturer of oral nirmatrelvir-ritonavir.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Posted July 2024
Further Support and Information on COVID-19
Read this next
Medicaid Unwinding Linked to Disruption of Chronic Medication Therapy in Youth
FRIDAY, May 16, 2025 -- In young patients, especially young adults, Medicaid unwinding associated with the COVID-19 pandemic disrupted chronic medication therapy, according to a...
No Link Found Between COVID-19 Vaccination During Pregnancy and Spontaneous Abortion
THURSDAY, May 15, 2025 -- There is no association between COVID-19 vaccination in pregnancy and spontaneous abortion, according to a study published online May 2...
Combined Flu, SARS-CoV-2 Vaccine as Effective as Individual Vaccines for Older Adults
FRIDAY, May 9, 2025 -- mRNA-1083 vaccine is noninferior and induces higher immune responses than recommended influenza and COVID-19 vaccines against several influenza strains and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.